Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.

[1]  M. Goldman,et al.  Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial. , 2015, International journal of MS care.

[2]  R. Motl,et al.  Accelerometry as a measure of walking behavior in multiple sclerosis , 2013, Acta neurologica Scandinavica.

[3]  Frances Lynn,et al.  Timed 25-Foot Walk , 2013, Neurology.

[4]  A. Blight,et al.  Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis , 2011, Current medical research and opinion.

[5]  L. Dibble,et al.  Ambulatory Activity in Individuals With Multiple Sclerosis , 2011, Journal of neurologic physical therapy : JNPT.

[6]  L. Krupp,et al.  A phase 3 trial of extended release oral dalfampridine in multiple sclerosis , 2010, Annals of neurology.

[7]  L. Krupp,et al.  Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial , 2009, The Lancet.

[8]  Jeffrey A. Cohen,et al.  Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls , 2008, Multiple sclerosis.

[9]  Jaana Paltamaa,et al.  Measuring Deterioration in International Classification of Functioning Domains of People With Multiple Sclerosis Who Are Ambulatory , 2008, Physical Therapy.

[10]  A J Thompson,et al.  Measuring the impact of MS on walking ability , 2003, Neurology.

[11]  N. Larocca.  Impact of Walking Impairment in Multiple Sclerosis , 2011, The patient.